Dr. O'Shaughnessy on Negative TNBC Iniparib Results

Video

Dr. Joyce O'Shaughnessy from Baylor Sammons Cancer Center on Negative TNBC Iniparib Trial Results

Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that iniparib's mechanism of action (MOA) is still under intensive study and has been under examination since the drug was first discovered.

Despite its recent negative triple negative breast cancer (TNBC) trial results O'Shaughnessy believes iniparib will become interesting once again. She describes that in a physiological concentration you do no inhibit PARP but in higher concentrations inhibition does occur. She believes that once the MOA is fully understood more options will be available.

Other trials are currently underway examining iniparib; options are becoming clear, such as its single agent use in BRCA2 mutated pancreatic cancer. It is still being investigated in TNBC, which O'Shaughnessy believes is still too broad of a category. A subset of patients in the TNBC trial demonstrated a benefit to the drug; trials still need to be conducting to pinpoint this subset of patients.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD